Meridian Bioscience, Inc. Financials

Market Capitalization $1.47 Billion as of Jan. 1, 2023

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-0.19
Forward PE	-2.50
Price to Sales TTM	C$0.36
Price to Book MRQ	C$0.25
Enterprise to Revenue	0.40
Enterprise to EBITDA	-1.33

Financial Reports as of Dec. 31, 2022

Financials

Fiscal Year Ends	2022-12-31
Most Recent Quarter	2022-12-31
Profit Margin	-190.51%
Operating Margin	-52.83%
Return on Assets TTM	-10.24%
Return on Equity TTM	-78.09%

Income Statement

Revenue TTM	C$25,411,812
Revenue per Share TTM	C$0.07
Quarterly Revenue Growth	3.20%
Gross Profit TTM	C$8,114,984
EBITDA	C$1,921,373
Net Income to Common TTM	C$-48,413,392
Diluted EPS TTM	C$-0.16
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	C$2,454,832
Total Cash per Share MRQ	C$0.01
Total Debt MRQ	C$
Total Debt to Equity MRQ	9.07
Current Ratio MRQ	3.15
Book Value per Share MRQ	C$0.10

Cash Flow

Operating Cash Flow TTM	C$-6,192,763
Levered Free Cash Flow TTM	C$-1,710,113

VIVO Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	370,896,992
Float Shares	332,060,256
Avg 10 Volume	356,577
Avg 30 Volume	None
Shares Short	543,253
Short Ratio	5.95
Short % of Shares	%
% Held by Insiders	10.36%
% Held by Institutions	0.00%

Stock Price Summary

Beta	2.12
Fifty Two Week Low	C$0.02
Fifty Two Week High	C$0.08
Fifty Two Week Change	-0.64%
Day 50 MA	C$0.02
Day 200 MA	C$0.03

Dividends and Splits

Forward Annual Dividend Rate	C$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	C$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date